Australia Antibody Drug Conjugates Market Size & Outlook
Related Markets
Australia antibody drug conjugates market highlights
- The Australia antibody drug conjugates market generated a revenue of USD 361.4 million in 2024 and is expected to reach USD 1,031.0 million by 2033.
- The Australia market is expected to grow at a CAGR of 12.4% from 2025 to 2033.
- In terms of segment, breast cancer was the largest revenue generating application in 2024.
- Urothelial Carcinoma is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2024 | USD 361.4 million |
| Market revenue in 2033 | USD 1,031.0 million |
| Growth rate | 12.4% (CAGR from 2025 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Urothelial Carcinoma |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Blood Cancer, Urothelial Carcinoma, Ovarian Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Australia accounted for 2.9% of the global antibody drug conjugates market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,442.0 million by 2033.
Breast cancer was the largest segment with a revenue share of 40.95% in 2024. Horizon Databook has segmented the Australia antibody drug conjugates market based on breast cancer, blood cancer, urothelial carcinoma, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.
Australia, with an age-standardized rate of 452.4 per 100,000 population, has one of the highest rates of cancers in the world, as per the International Agency for Research on Cancer. Given this high prevalence of cancer, the country has focused on providing payment assistance for certain ADC drugs.
For instance, Adcetris, indicated for the treatment of Hodgkin’s lymphoma, has been publicly funded through the Pharmaceutical Benefits Scheme (PBS) to ease out-of-pocket expenditure by the public. Australia has one of the highest ASRs of Hodgkin’s lymphoma in the world, with further growth projected in its rapidly increasing elderly population.
Australian firms such as Avipep Therapeutics have ADC drugs indicated for multiple adenocarcinomas, Hodgkin’s lymphoma, cutaneous lymphoma, systematics anaplastic large cell lymphoma, and TBA in their research pipeline. Products such as Trodelvy are currently under regulatory review for the treatment of TNBC.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| ADC Therapeutics SA | View profile | 274 | Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 | https://www.adctherapeutics.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | https://india-consumer.gsk.com/ |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
Australia antibody drug conjugates market size, by application, 2021-2033 (US$M)
Australia Antibody Drug Conjugates Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
